Profarma Distribuidora refines strategy in Brazilian pharma wholesale, shares on B3 under scrutiny
Published on 06/25/2026 at 20:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 20:22.
Profarma Distribuidora (BRPFRMACNOR8) remains a focused player in Brazil's pharmaceutical wholesale and retail market. The company is listed on B3 in Sao Paulo, and investors increasingly compare it with sector peer Raia Drogasil when they assess liquidity, profitability and scale in the local healthcare segment.
Operational footprint in Brazil
Profarma Distribuidora operates as a distributor of branded and generic medicines, health products and related items across Brazil, supplying pharmacies, hospitals and clinics through a regional logistics network, as described in its corporate profile on the company website Profarma corporate information.
The group combines distribution activities with a pharmacy retail presence via banners that target different income segments, and it competes in a market characterized by large chains such as Raia Drogasil and Pague Menos according to sector commentary in Brazilian financial media Reuters overview of Brazilian drug retailers.
Financial profile and analyst view
Recent analyst and market data compiled for the ticker PFRM3 on B3 show that Profarma Distribuidora continues to report modest profitability with tight margins, as is typical for pharmaceutical wholesalers, and that balance-sheet deleveraging remains a key focus for investors following the stock on Brazilian broker platforms that aggregate earnings and consensus data MarketScreener Profarma snapshot.
Market commentary for Brazilian healthcare names indicates that institutional investors monitor free cash flow generation and working-capital swings closely in this segment, since inventory and receivables management strongly influence returns for distributors, and they typically assess Profarma alongside listed peers such as Raia Drogasil and Dimed in that context, based on analyst notes cited by local financial portals that cover B3-listed healthcare companies B3 information on PFRM3.
All news and analysis on the Profarma Distribuidora shares
Further coverage, regulatory disclosures and background pieces on Profarma Distribuidora can be found in the ad-hoc-news.de topic section and on the company investor-relations pages.
How Profarma makes its money
Profarma Distribuidora generates most of its revenue by purchasing pharmaceutical and healthcare products from manufacturers and selling them on to pharmacies, hospitals and other healthcare providers across Brazil, collecting a distribution margin and service fees for logistics, credit and related services.
Where the stock trades today
Profarma Distribuidora shares trade on B3 in Sao Paulo under the ticker PFRM3; current price and market-cap data are published intraday by the Brazilian exchange in Brazilian real.
Profarma Distribuidora at a glance
- Company: Profarma Distribuidora de Produtos Farmaceuticos S.A.
- ISIN: BRPFRMACNOR8
- WKN: A1C6V0
- Ticker: PFRM3
- Trading venue: B3 Sao Paulo
- Price (as of 2026-06-25, 20:22): data in BRL published by B3
- Market cap: data in BRL reported by B3 for PFRM3
- Sector / industry: Healthcare - Pharmaceutical distribution and retail
- Index membership: not a member of Brazil's main benchmark indices such as Ibovespa according to recent B3 index compositions
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
